Loading clinical trials...
Loading clinical trials...
Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.
Conditions
Interventions
Arikayce™ 560 mg
Placebo for 560 mg
+3 more
Locations
19
United States
Birmingham, Alabama, United States
Los Angeles, California, United States
Miami, Florida, United States
Orlando, Florida, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Start Date
January 1, 2008
Primary Completion Date
June 1, 2009
Completion Date
June 1, 2009
Last Updated
June 4, 2019
NCT02417740
NCT06616857
NCT07108153
NCT02740868
NCT07274631
NCT07303621
Lead Sponsor
Insmed Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions